Efficacy of fluconazole prophylaxis for prevention of invasive fungal infection in extremely low birth weight infants

Pediatric Infectious Disease Journal

Volumn 29, Issue 4, 2010, Pages 352-356

  Aziz, Mariam ^a   Patel, Aloka L ^b   Losavio, Jennifer ^c   Iyengar, Anjali ^b   Berven, Michael ^c   Schloemer, Nathan ^b   Jakubowicz, Andrew ^b   Mathai, Tina ^b   McAuley, James B ^a,b  

^a Departments of Preventive Medicine   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c RUSH MEDICAL COLLEGE   (United States)

Author keywords

Candida; Fluconazole; Invasive fungal infection; Premature infant; Prophylaxis

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; DEXAMETHASONE; FLUCONAZOLE; FLUCYTOSINE; HYDROCORTISONE;

ADD ON THERAPY; ARTICLE; ARTIFICIAL VENTILATION; BIRTH WEIGHT; BRAIN ABSCESS; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CATHETERIZATION; CHOLESTASIS; CHORIOAMNIONITIS; CONFOUNDING VARIABLE; CONTROLLED STUDY; DATA EXTRACTION; DEMOGRAPHY; DRUG EFFICACY; ENDOCARDITIS; EXTREMELY LOW BIRTH WEIGHT; EYE INFLAMMATION; FEMALE; GESTATIONAL AGE; HUMAN; INFANT; INFANT FEEDING; INFECTION PREVENTION; INFECTION RATE; INFECTION RISK; INTESTINE PERFORATION; KIDNEY ABSCESS; LIVER ABSCESS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MYCOSIS; NECROTIZING ENTEROCOLITIS; NEWBORN INTENSIVE CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEPSIS; SPLEEN ABSCESS; TOTAL PARENTERAL NUTRITION; TREATMENT DURATION; TREATMENT OUTCOME; VENTILATOR; YARROWIA LIPOLYTICA;

EID: 77950284302     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181bf8eb1     Document Type: Article

References (46)

1. Kaufman D, Fairchild KD. Clinical microbiology of bacterial and fungal sepsis in very-low-birth-weight infants [table of contents]. Clin Microbiol Rev. 2004;17:638-680.
2. Devlin RK. Invasive fungal infections caused by Candida and Malassezia species in the neonatal intensive care unit. Adv Neonat Care. 2006;6:68-77; quiz 78-79.
3. Stoll BJ, Hansen N, Fanaroff AA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD neonatal research network. Pediatrics. 2002;110(2 Pt 1):285-291.
4. Stoll BJ, Gordon T, Korones SB, et al. Late-onset sepsis in very low birth weight neonates: a report from the national institute of child health and human development neonatal research network. JPediatr. 1996;129:63-71.
5. Kossoff EH, Buescher ES, Karlowicz MG. Candidemia in a neonatal intensive care unit: trends during fifteen years and clinical features of 111 cases. Pediatr Infect Dis J. 1998;17:504-508.
6. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis. 2004;38:161-189.
7. Healy CM, Campbell JR, Zaccaria E, et al. Fluconazole prophylaxis in extremely low birth weight neonates reduces invasive candidiasis mortality rates without emergence of fluconazole-resistant Candida species. Pediatrics. 2008;121:703-710.
8. Kicklighter SD, Springer SC, Cox T, et al. Fluconazole for prophylaxis against candidal rectal colonization in the very low birth weight infant. Pediatrics. 2001;107:293-298.
9. Kaufman D, Boyle R, Hazen KC, et al. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med. 2001;345:1660-1666.
10. Aghai ZH, Mudduluru M, Nakhla TA, et al. Fluconazole prophylaxis in extremely low birth weight infants: association with cholestasis. JPerinatol. 2006;26:550-555.
11. Bertini G, Perugi S, Dani C, et al. Fluconazole prophylaxis prevents invasive fungal infection in high-risk, very low birth weight infants. J Pediatr. 2005;147:162-165.
12. Healy CM, Baker CJ, Zaccaria E, et al. Impact of fluconazole prophylaxis on incidence and outcome of invasive candidiasis in a neonatal intensive care unit. JPediatr. 2005;147:166-171.
13. Kaufman D, Boyle R, Hazen KC, et al. Twice weekly fluconazole prophylaxis for prevention of invasive Candida infection in high-risk infants of <1000 grams birth weight. J Pediatr., 2005, 147, 172-179.
14. Manzoni P, Arisio R, Mostert M, et al. Prophylactic fluconazole is effective in preventing fungal colonization and fungal systemic infections in preterm neonates: a single-center, 6-year, retrospective cohort study. Pediatrics. 2006;117:e22-e32.
15. Manzoni P, Leonessa M, Galletto P, et al. Routine use of fluconazole prophylaxis in a neonatal intensive care unit does not select natively fluconazole-resistant Candida subspecies. Pediatr Infect Dis J. 2008;27: 731-737.
16. McCrossan BA, McHenry E, O'Neill F, et al. Selective fluconazole prophylaxis in high-risk babies to reduce invasive fungal infection. Arch Dis Child Fetal Neonatal Ed. 2007;92:F454-F458.
17. Uko S, Soghier LM, Vega M, et al. Targeted short-term fluconazole prophylaxis among very low birth weight and extremely low birth weight infants. Pediatrics. 2006;117:1243-1252.
18. Manzoni P, Stolfi I, Pugni L, et al. A multicenter, randomized trial of prophylactic fluconazole in preterm neonates. N Engl J Med. 2007;356: 2483-2495.
19. Clerihew L, Austin N, McGuire W. Prophylactic systemic antifungal agents to prevent mortality and morbidity in very low birth weight infants. Cochrane Database Syst Rev. 2007:CD003850.
20. Neely MN, Schreiber JR. Fluconazole prophylaxis in the very low birth weight infant: not ready for prime time. Pediatrics. 2001;107:404-405.
21. Fanaroff AA. Fluconazole for the prevention of fungal infections: get ready, get set, caution. Pediatrics. 2006;117:214-215.
22. Walsh MC, Kliegman RM. Necrotizing enterocolitis: treatment based on staging criteria. Pediatr Clin North Am. 1986;33:179-201.
23. Baley JE, Kliegman RM, Boxerbaum B, et al. Fungal colonization in the very low birth weight infant. Pediatrics. 1986;78:225-232.
24. Pappu-Katikaneni LD, Rao KP, Banister E. Gastrointestinal colonization with yeast species and Candida septicemia in very low birth weight infants. Mycoses. 1990;33:20-23.
25. Benjamin DK Jr, Poole C, Steinbach WJ, et al. Neonatal candidemia and end-organ damage: a critical appraisal of the literature using meta-analytic techniques. Pediatrics. 2003;112(3 Pt 1):634-640.
26. Friedman S, Richardson SE, Jacobs SE, et al. Systemic Candida infection in extremely low birth weight infants: short term morbidity and long term neurodevelopmental outcome. Pediatr Infect Dis J. 2000;19:499-504.
27. Lee BE, Cheung PY, Robinson JL, et al. Comparative study of mortality and morbidity in premature infants (birth weight, <1250 g) with candidemia or candidal meningitis., Clin Infect Dis., 1998, 27, 559-565.
28. Edmond MB, Wallace SE, McClish DK, et al. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis. 1999;29:239-244.
29. Benjamin DK Jr, Stoll BJ, Fanaroff AA, et al. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics. 2006;117:84-92.
30. Chapman RL, Faix RG. Persistently positive cultures and outcome in invasive neonatal candidiasis. Pediatr Infect Dis J. 2000;19:822-827.
31. Karlowicz MG, Hashimoto LN, Kelly RE Jr, et al. Should central venous catheters be removed as soon as candidemia is detected in neonates? Pediatrics. 2000;106:E63.
32. Saiman L, Ludington E, Pfaller M, et al. Risk factors for candidemia in neonatal intensive care unit patients. The national epidemiology of mycosis survey study group. Pediatr Infect Dis J. 2000;19:319-324.
33. Manzoni P, Farina D, Leonessa M, et al. Risk factors for progression to invasive fungal infection in preterm neonates with fungal colonization. Pediatrics. 2006;118:2359-2364.
34. Brammer KW, Coates PE. Pharmacokinetics of fluconazole in pediatric patients. Eur J Clin Microbiol Infect Dis. 1994;13:325-329.
35. Saxen H, Hoppu K, Pohjavuori M. Pharmacokinetics of fluconazole in very low birth weight infants during the first two weeks of life. Clin Pharmacol Ther. 1993;54:269-277.
36. Huang YC, Li CC, Lin TY, et al. Association of fungal colonization and invasive disease in very low birth weight infants. Pediatr Infect Dis J. 1998;17:819-822.
37. Aucott SW, Donohue PK, Northington FJ. Increased morbidity in severe early intrauterine growth restriction. J Perinatol. 2004;24:435-440.
38. Shamir R, Maayan-Metzger A, Bujanover Y, et al. Liver enzyme abnormalities in gram-negative bacteremia of premature infants. Pediatr Infect Dis J. 2000;19:495-498.
39. Steinbach M, Clark RH, Kelleher AS, et al; Pediatrix Amino-Acid Study Group. Demographic and nutritional factors associated with prolonged cholestatic jaundice in the premature infant. J Perinatol. 2008;28:129-135.
40. Sarvikivi E, Lyytikainen O, Soll DR, et al. Emergence of fluconazole resistance in a Candida parapsilosis strain that caused infections in a neonatal intensive care unit. J Clin Microbiol. 2005;43:2729-2735.
41. Long SS, Stevenson DK. Reducing Candida infections during neonatal intensive care: management choices, infection control, and fluconazole prophylaxis [comment]. J Pediatr. 2005;147:135-141.
42. Hachem R, Hanna H, Kontoyiannis D, et al. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer. 2008;112:2493-2499.
43. Hope W, Morton A, Eisen DP. Increase in prevalence of nosocomial non-candida albicans candidaemia and the association of Candida krusei with fluconazole use. JHosp Infect. 2002;50:56-65.
44. Price MF, LaRocco MT, Gentry LO. Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period. Antimicrob Agents Chemother. 1994;38:1422-1424.
45. Fridkin SK, Kaufman D, Edwards JR, et al. Changing incidence of candida bloodstream infections among NICU patients in the United States: 1995-2004. Pediatrics. 2006;117:1680-1687.
46. Yoder BA, Sutton DA, Winter V, et al. Resistant Candida parapsilosis associated with long term fluconazole prophylaxis in an animal model. Pediatr Infect Dis J. 2004;23:687-688.